Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by ANALIAS00on Feb 25, 2018 12:58pm
174 Views
Post# 27617235

SP vs #patients

SP vs #patients
We all speculated on the share price, But not many specified the # patient it would take to reach the expexted SP. Some expect a SP at $15, $20 and I also read $30 and more. So my question to you is: what is the # of patient it would take to match your expected SP ? If you are serions you should not have any calculation to do. You should have speculated on the # of patient(or sales) prior to Come up with a SP. Remember, the market was evaluated to be between 10000 to 12000 and of course it is impossible to reach close to 100%. I would say that 20% should be a minimim to have SP above 10.50, not considering Europe. And reaching 20% would be a great achievement. I doubt we will reach it but I would be more than satisfied about it since we should be sellier in Europe eventually. But again, what will be the real penetration rate after 2 full years ? 5,10 or 20%.?
Bullboard Posts